Copyright
©2014 Baishideng Publishing Group Inc.
World J Pharmacol. Dec 9, 2014; 3(4): 120-139
Published online Dec 9, 2014. doi: 10.5497/wjp.v3.i4.120
Published online Dec 9, 2014. doi: 10.5497/wjp.v3.i4.120
Figure 2 Phosphoprotein phosphatase 1 interacting proteins can be regulators, substrate or both.
Green represents positive regulation of phosphoprotein phosphatase 1 (PPP1) (in case of regulators) or PPP1-mediated upregulation of substrates. Red represents negative regulation of PPP1 (in case of regulators) or PPP1-mediated downregulation of substrates. Blue characterizes PPP1-interacting proteins (PIPs) exhibiting PPP1 targeting ability. Yellow corresponds to proteins that are identified as substrates, but whose interaction with PPP1 are not fully understood. ATM: Ataxia telangiectasia mutated; GSK3B: Glycogen synthase kinase-3 β; SMARCB1: SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1; BRCA1: Breast cancer type 1 susceptibility protein.
- Citation: Felgueiras J, Fardilha M. Phosphoprotein phosphatase 1-interacting proteins as therapeutic targets in prostate cancer. World J Pharmacol 2014; 3(4): 120-139
- URL: https://www.wjgnet.com/2220-3192/full/v3/i4/120.htm
- DOI: https://dx.doi.org/10.5497/wjp.v3.i4.120